EUVIMEDEUVIMED entdecken
Open Access

225 Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

A Paden King, Nicholas T Gutsche, Natarajan Raju, Stanley Fayn, Kwamena E Baidoo, Meghan M Bell, Colleen S Olkowski, Rolf E Swenson, Frank I Lin, Samira M Sadowski, Stephen S Adler, Nikki A Thiele und 3 weitere

Journal of Nuclear Medicine · 2023-04 · 64 (4) · 549-554

DOI: 10.2967/jnumed.122.264707 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 17.11.2022. Verfasst von A Paden King und 14 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Organometallic Compounds. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroendocrine tumors (NETs) express somatostatin receptors (SSTRs) 2 and 5. Modified variants of somatostatin, the cognate ligand for SSTR2 and SSTR5, are used in treatment for metastatic and locoregional disease. Peptide receptor radionuclide therapy with 177Lu-DOTATATE (DOTA-octreotate), a β-particle-emitting somatostatin derivative, has demonstrated survival benefit in patients with SSTR-positive NETs. Despite excellent results, a subset of patients has tumors that are resistant to treatment, and alternative agents are needed. Targeted α-particle therapy has been shown to kill tumors that are resistant to targeted β-particle therapy, suggesting that targeted α-particle therapy may offer a promising treatment option for patients with 177Lu-DOTATATE-resistant disease. Although DOTATATE can chelate the clinically relevant α-particle-emitting radionuclide 225Ac, the labeling reaction requires high temperatures, and the resulting radioconjugate has suboptimal stability.

Methods

We designed and synthesized MACROPATATE (MACROPA-octreotate), a novel radioconjugate capable of chelating 225Ac at room temperature, and assessed its in vitro and in vivo performance.

Results

MACROPATATE demonstrated comparable affinity to DOTATATE (dissociation constant, 21 nM) in U2-OS-SSTR2, a SSTR2-positive transfected cell line. 225Ac-MACROPATATE demonstrated superior serum stability at 37°C over time compared with 225Ac-DOTATATE. Biodistribution studies demonstrated higher tumor uptake of 225Ac-MACROPATATE than of 225Ac-DOTATATE in mice engrafted with subcutaneous H69 NETs. Therapy studies showed that 225Ac-MACROPATATE exhibits significant antitumor and survival benefit compared with saline control in mice engrafted with SSTR-positive tumors. However, the increased accumulation of 225Ac-MACROPATATE in liver and kidneys and subsequent toxicity to these organs decreased its therapeutic index compared with 225Ac-DOTATATE.

Conclusion

225Ac-MACROPATATE and 225Ac-DOTATATE exhibit favorable therapeutic efficacy in animal models. Because of elevated liver and kidney accumulation and lower administered activity for dose-limiting toxicity of 225Ac-MACROPATATE, 225Ac-DOTATATE was deemed the superior agent for targeted α-particle peptide receptor radionuclide therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOrganometallic CompoundsMiceAnimalsOctreotideTissue DistributionSomatostatinReceptors, SomatostatinRadioisotopesRadiopharmaceuticals

Stichwörter der Autor:innen

actiniumneuroendocrine tumorsoctreotateoncologysomatostatintargeted α-therapy

Substanzen

OctreotideOrganometallic CompoundsSomatostatinReceptors, SomatostatinRadioisotopesRadiopharmaceuticals

Autor:innen und Institutionen

  • Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Chemical and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
  • Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee.
  • Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, New York; and.

Förderung

  • NIBIB NIH HHS

Zitieren

APA

King, A. P., Gutsche, N. T., Raju, N., Fayn, S., Baidoo, K. E., Bell, M. M., Olkowski, C. S., Swenson, R. E., Lin, F. I., Sadowski, S. M., Adler, S. S., Thiele, N. A., Wilson, J. J., Choyke, P. L., & Escorcia, F. E. (2023). 225 Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. Journal of Nuclear Medicine, 64(4), 549-554. https://doi.org/10.2967/jnumed.122.264707

Vancouver

King AP, Gutsche NT, Raju N, Fayn S, Baidoo KE, Bell MM, et al. 225 Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. Journal of Nuclear Medicine. 2023;64(4):549-554. doi:10.2967/jnumed.122.264707

BibTeX
@article{King2023,
  author = {King, A Paden and Gutsche, Nicholas T and Raju, Natarajan and Fayn, Stanley and Baidoo, Kwamena E and Bell, Meghan M and Olkowski, Colleen S and Swenson, Rolf E and Lin, Frank I and Sadowski, Samira M and Adler, Stephen S and Thiele, Nikki A and Wilson, Justin J and Choyke, Peter L and Escorcia, Freddy E},
  title = {225 Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {4},
  pages = {549--554},
  doi = {10.2967/jnumed.122.264707}
}
Kostenlos starten →